Synthesized analogs from the heterocyclic classes of imidazo[1,5-a]quinoxaline and pyrazolo[1,5-a]quinoxaline have been evaluated for their ability to impede the activation of NF-kB via modulation of TLR receptors.5 Additionally, compounds from the pyrrolo[1,2-a]quinoxaline series have been identified as promising candidates for inhibiting the main protease of SARS-CoV-2 and as activators of Sirt6, which are hypothesized to suppress the virus.6,18 These findings underscore the therapeutic potential of novel heterocyclic compounds in the ongoing battle against COVID-19. Here, SIRT6 is linked to COVID-19.